Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Restoring Physiological Normoxia as an Adjuvant Strategy to Improve Cancer Treatment Outcomes.

Nature and science of sleep·2026

Same author

Clinical Complete Response and Organ Preservation Strategies in Rectal Cancer: A Real-World Single-Center Experience Clinical Complete Response and Organ Preservation in Rectal Cancer.

Cancers·2026

Same author

Drug-drug interactions in adjuvant and neoadjuvant breast cancer therapy.

European journal of hospital pharmacy : science and practice·2026

Same author

Bone Health in Metastatic Hormone-Sensitive Prostate Cancer: Where We Stand and Where We Can Improve.

Cancers·2025

Same author

miR-106b-5p as a Central Regulator of Cancer Progression and Chemotherapy-Induced Cardiotoxicity: From Molecular Mechanisms to Clinical Translation.

International journal of molecular sciences·2025

Same author

Incidence and Survival of IDH-Wildtype Glioblastoma and IDH-Mutant Astrocytoma by Treatment and Sex: A Regional Study in Spain (2011-2021).

Medical sciences (Basel, Switzerland)·2025

Search research articles

Related Experiment Video

Updated: Sep 16, 2025

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

Apalutamide and Stereotactic Body Radiotherapy in Metastatic Hormone-Sensitive Prostate Cancer: Multicenter

Juan A Encarnación^1,2,3, Virginia Morillo Macías⁴, Isabel De la Fuente Muñoz¹

¹Department Radiation Oncology, Hospital Clínico Universitario Virgen de la Arrixaca, 30120 Murcia, Spain.

|July 12, 2025

Summary

Combining apalutamide with stereotactic body radiotherapy (SBRT) shows high local control and progression-free survival in metastatic hormone-sensitive prostate cancer (mHSPC). This well-tolerated treatment offers promising results for managing mHSPC effectively.

Keywords:

PSA response SBRT androgen receptor signaling inhibitors apalutamide metastasis-directed therapy metastatic prostate cancer oligometastatic disease real-world study stereotactic body radiotherapy

More Related Videos

Retzius-Sparing Robot-Assisted Radical Prostatectomy

Retzius-Sparing Robot-Assisted Radical Prostatectomy

Published on: May 19, 2022

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy

Published on: May 8, 2018

Related Experiment Videos

Last Updated: Sep 16, 2025

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

Retzius-Sparing Robot-Assisted Radical Prostatectomy

Retzius-Sparing Robot-Assisted Radical Prostatectomy

Published on: May 19, 2022

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy

Published on: May 8, 2018

Area of Science:

Oncology
Radiation Oncology
Medical Oncology

Background:

Metastatic hormone-sensitive prostate cancer (mHSPC) management integrates androgen receptor signaling inhibitors (ARSIs) and metastasis-directed therapies (MDTs).
Stereotactic body radiotherapy (SBRT) provides precise local control, but real-world data on its combination with apalutamide is limited.

Purpose of the Study:

To evaluate the efficacy and safety of combining apalutamide with SBRT in patients with mHSPC.
To assess progression-free survival (PFS), local control (LC), and treatment-related toxicity.

Main Methods:

Multicenter retrospective cohort study of 134 mHSPC patients treated with apalutamide and SBRT.
Analysis of PSA kinetics, radiological response, PFS, LC, and safety outcomes.
Evaluation based on PSA thresholds and treatment timing.

Main Results:

High local control (99.3%) and 95.5% progression-free survival at 28 months median follow-up.
Complete radiological response in 87.5% and ultralow PSA levels (≤0.02 ng/mL) in 68.4% of patients.
Undetectable PSA and complete radiological response independently predicted improved PFS; low toxicity (2.2% grade ≥3).

Conclusions:

Combination of apalutamide and SBRT demonstrates high local and systemic disease control with minimal toxicity in real-world mHSPC management.
This therapeutic approach may defer systemic treatment escalation and delay castration resistance.
Further prospective studies are recommended to validate these findings.